Dans le même genre
DePuy Synthes se sépare de Johnson & Johnson
ESTIMÉCONFIANCE 71 %dans 281 joursLe 10-Q de J&J pour le trimestre clos le 28 juin 2026 vise une « finalisation sous 18 à 24 mois après l'annonce initiale » du 14 octobre 2025 (de la mi-avril à la mi-octobre 2027), et le directeur financier Joseph Wolk a déclaré en juillet que J&J « est en bonne voie pour une séparation à la mi-2027 » (Bloomberg) ; « mi-2027 » est compris comme le milieu de l'année, soit le 1er juillet 2027, qui se situe dans cette fenêtre.[1]L'activité orthopédie de Johnson & Johnson doit quitter le groupe sous le nom de DePuy Synthes – par scission non imposable ou par cession, Apollo étant en discussions autour de 20 milliards de dollars – et J&J affirme être en bonne voie pour une séparation à la mi-2027.0.79J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
CONFIRMÉCONFIANCE 90 %il y a 344 joursThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.73J&J Completes Its $1 Billion Acquisition of Firefly Bio
CONFIRMÉCONFIANCE 87 %il y a 56 jours"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.63J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
CONFIRMÉCONFIANCE 82 %il y a 58 joursJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.61Abbott Agrees to Buy Exact Sciences for $21 Billion
CONFIRMÉCONFIANCE 86 %il y a 307 joursThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.60La Station spatiale internationale promise à une désorbitation contrôlée
PROGRAMMÉCONFIANCE 77 %dans 4,3 ansDonné comme prévu, selon la source : « La NASA[3] et ses partenaires internationaux prévoient de désorbiter intentionnellement le laboratoire orbital vers 2030 ou peu après. »La NASA prévoit de retirer l'ISS, âgée de 25 ans, en la dirigeant vers une zone reculée du Pacifique Sud à l'aide d'un véhicule de désorbitation conçu par SpaceX.$843M0.59Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
CONFIRMÉCONFIANCE 87 %il y a 120 joursLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.58Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMÉCONFIANCE 88 %il y a 23 joursThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.58Inside Tesla's $5 Billion Gigafactory - Visual Capitalist
The $5 Billion Tesla Gigfactory will set a new precedent for economies of scale in battery production, creating demand for graphite, cobalt, and lithium. The name gigafactory comes from the plant's planned annual battery production capacity of 35 gigawatt-hours, which Tesla said on Wednesday it would achieve by 2018.$5B0.58Huang: $1 trillion in Blackwell and Vera Rubin orders through 2027
CONFIRMÉCONFIANCE 90 %il y a 191 joursCNBC's[1] 16 March 2026 coverage of the GTC 2026 keynote reports the remark.At GTC 2026, Huang said he expects purchase orders for Blackwell and Vera Rubin to reach $1 trillion through 2027, up from the $500 billion outlook given the previous year.0.58Babcock & Wilcox Gets Go-Ahead on $2.4B Base Electron Power Plant
CONFIRMÉCONFIANCE 87 %il y a 203 joursStated as done, per babcock.com[1]: "(AKRON, Ohio - March 4, 2026) - Babcock & Wilcox ... announced today that it has received full notice to proceed on a $2.4 billion design-build agreement"; the Business Wire copy on Yahoo Finance is timestamped 11:30 UTC.Babcock & Wilcox received full notice to proceed on a $2.4 billion design-build contract with Base Electron, an Applied Digital-backed power producer, for 1.2 GW of gas-fired boiler and steam turbine capacity to supply Applied Digital AI Factory campuses.$2.4B0.58Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
CONFIRMÉCONFIANCE 87 %il y a 176 joursThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.58
